Table 1 Distribution of fascin immunoreactivity in the 220 NSCLC
From: Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer
Immunoreactive cells (%) a | Immunolabelling intensity (%) b | |||||
|---|---|---|---|---|---|---|
Histotype | None | 5–60% | >60% | None | Low | High |
Adenocarcinoma (N=96) | 21 (22) | 41 (43) | 34 (35) | 21 (22) | 43 (45) | 32 (33) |
Adenosquamous (N=2) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 2 (100) |
Squamous cell carcinoma (N=116) | 2 (2) | 14 (12) | 100 (86) | 2 (2) | 45 (47) | 69 (72) |
Large cell carcinoma (N=6) | 1 (17) | 1 (17) | 4 (66) | 1 (17) | 0 | 5 (83) |
